# A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes

Study · id `cardio:ct-nct07271251` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07271251](<https://clinicaltrials.gov/study/NCT07271251>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07271251

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 267 participants.

## Technical summary

Registry record NCT07271251. Randomized; no masking; primary purpose treatment. Start 2025-12-01 (actual); primary completion 2026-06-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 267 participants (enrolled count; ClinicalTrials.gov record NCT07271251, source copy `cardio:ctgov-nct07271251-2026-08-13`, retrieved 2026-10-26)
- Started: 2025-12-01 (actual) (ClinicalTrials.gov record NCT07271251, source copy `cardio:ctgov-nct07271251-2026-08-13`, retrieved 2026-10-26)
- Primary completion: 2026-06-29 (actual) (ClinicalTrials.gov record NCT07271251, source copy `cardio:ctgov-nct07271251-2026-08-13`, retrieved 2026-10-26)
- Completion: 2026-08-04 (actual) (ClinicalTrials.gov record NCT07271251, source copy `cardio:ctgov-nct07271251-2026-08-13`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT07271251, source copy `cardio:ctgov-nct07271251-2026-08-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07271251-2026-08-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): Oral semaglutide
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 15dfd6f8af43091657717462ccc7b149f3c439662f6c81ea94b9591c290b56dc
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
